Gen: Top 10 pharmaceutical companies in 2014
-
Last Update: 2014-08-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Biovalley, Aug 12, 2014 (Aug 11, 2014) - on Aug 11, genetic engineering & Biotechnology news (Gen) released the top 10 list of global pharmaceutical companies' market value in 2014 The list is based on the market cap calculated on the stock exchange or other public sources on August 5 Data from non-U.S companies convert currencies into dollars based on the August 5 exchange rate Compared with the list in July 2013, the rankings of several companies have changed A significant factor is the change in currency In the 2014 list, six non-U.S companies benefited from a particularly strong pound, a stronger euro and a slightly stronger Swiss Franc (compared to the US dollar) This explains the rise of some non-U.S companies in the 2014 list, such as Novartis, which topped Pfizer in third place, Bayer, and Azn, which even squeezed into the top nine from the top 10 The market value of the other three non-U.S companies with unchanged positions also expanded significantly Two American companies that failed to make the top 10 list this time: Eli Lilly and BMS Lilly, like AstraZeneca, has been stuck in the patent cliff of blockbuster drugs in recent years, while clinical development has been frustrated one after another However, Lilly differs from AstraZeneca in that it does not benefit from the pound And Bristol Myers Squibb, with a market value of $82.86 billion, ranked 11th, was overtaken by abbvie Aberdeen's market value soared in mid July when it bought shire, a British pharmaceutical company, for about $55bn in cash and shares Original English: Top 10 Pharma farms of 2014 http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.